Search

Your search keyword '"Lefort, Mathilde"' showing total 39 results
Start Over Author "Lefort, Mathilde"
39 results on '"Lefort, Mathilde"'

4. Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression

Author

Kammerer-Jacquet, Solène-Florence, Brunot, Angelique, Lefort, Mathilde, Bayat, Sahar, Peyronnet, Benoit, Verhoest, Gregory, Mathieu, Romain, Lespagnol, Alexandra, Mosser, Jean, Laguerre, Brigitte, Ravaud, Alain, Bernhard, Jean-Christophe, Dupuis, Frantz, Yacoub, Mokrane, Belaud-Rotureau, Marc-Antoine, Bensalah, Karim, and Rioux-Leclercq, Nathalie

Published
2019
Full Text
View/download PDF

5. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.

Author

Jouvenot, Guillaume, Courbon, Guilhem, Lefort, Mathilde, Rollot, Fabien, Casey, Romain, Le Page, Emmanuelle, Michel, Laure, Edan, Gilles, de Seze, Jérome, Kremer, Laurent, Bigaut, Kevin, Vukusic, Sandra, Mathey, Guillaume, Ciron, Jonathan, Ruet, Aurélie, Maillart, Elisabeth, Labauge, Pierre, Zephir, Hélène, Papeix, Caroline, and Defer, Gilles

Published
2024
Full Text
View/download PDF

7. Impact of education level on multiple sclerosis disability progression in France

Author

Lefort, Mathilde, Dejardin, O., Calocer, F., Defer, G., Leray, E., Jonchère, Laurent, Centre de Recherches sur l'Action Politique en Europe (ARENES), Université de Rennes (UR)-Institut d'Études Politiques [IEP] - Rennes-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Centre National de la Recherche Scientifique (CNRS), École des Hautes Études en Santé Publique [EHESP] (EHESP), Département Méthodes quantitatives en santé publique (METIS), Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers (ANTICIPE), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Recherche sur les services et le management en santé (RSMS), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Collectif de recherche handicap, autonomie et société inclusive (CoRHASI), EDMUS Foundation, and ARSEP Foundation

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

International audience; Meeting Abstract O15438th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-SclerosisAmsterdam, NETHERLANDSOCT 26-28, 2022

Published
2022

8. A cross-sectional study on infectious health risks regarding freshwater sports practice in Brittany, France

Author

Velardo, Fanny, primary, Bouziri, Hanifa, additional, Adélaïde, Lucie, additional, Oliosi, Emma, additional, Layan, Maylis, additional, Descamps, Alexandre, additional, Berthod, Delphine, additional, Patlán-Hernández, Alan R., additional, Ledrans, Martine, additional, Pivette, Mathilde, additional, Lefort, Mathilde, additional, Roux, Jonathan, additional, and Crépey, Pascal, additional

Published
2022
Full Text
View/download PDF

9. Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts

Author

Sharmin, Sifat, Lefort, Mathilde, Andersen, Johanna Balslev, Leray, Emmanuelle, Horakova, Dana, Eva Kubala Havrdova, Alroughani, Raed, Ayuso, Guillermo Izquierdo, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, Mccombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Prevost, Julie, Maimone, Davide, Skibina, Olga, Buzzard, Katherine, Walt, Anneke, Wijmeersch, Bart, Csepany, Tunde, Spitaleri, Daniele Litterio A., Vucic, Ostoja, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurelie, Seze, Jerome, Maillart, Elisabeth, Zephir, Helene, Labauge, Pierre, Defer, Gilles, Lebrun-Frenay, Christine, Moreau, Thibault, Berger, Eric, Clavelou, Pierre, Pelletier, Jean, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanche, Jean-Philippe, Maurousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Celine, Nifle, Chantal, Laplaud, David, Koch-Henriksen, Nils, Sellebjerg, Finn Thorup, Soerensen, Per Soelberg, Pfleger, Claudia Christina, Rasmussen, Peter Vestergaard, Jensen, Michael Broksgaard, Frederiksen, Jette Lautrup, Bramow, Stephan, Mathiesen, Henrik Kahr, Schreiber, Karen Ingrid, Magyari, Melinda, Vukusic, Sandra, Butzkueven, Helmut, and Kalincik, Tomas

Published
2021

10. Disability progression in multiple sclerosis patients using early first‐line treatments.

Author

Lefort, Mathilde, Vukusic, Sandra, Casey, Romain, Edan, Gilles, Leray, Emmanuelle, Cotton, François, De Sèze, Jérôme, Douek, Pascal, Guillemin, Francis, Laplaud, David, Lebrun‐Frenay, Christine, Pachot, Alexandre, Moreau, Thibault, Olaiz, Javier, Pelletier, Jean, Rigaud‐Bully, Claire, Stankoff, Bruno, Zephir, Hélène, Marignier, Romain, and Debouverie, Marc

Subjects
*MULTIPLE sclerosis, *GLATIRAMER acetate, *DISABILITIES, *OLDER patients, *TREATMENT delay (Medicine), *PEOPLE with disabilities
Abstract

Background and purpose: Therapeutic management of relapsing–remitting multiple sclerosis (RRMS) has evolved towards early treatment. The objective was to assess the impact of early treatment initiation on disability progression amongst RRMS first‐line‐treated patients. Methods: This study included all incident RRMS cases starting interferon or glatiramer acetate for the first time from 1 January 1996 to 31 December 2012 (N = 5279) from 10 MS expert Observatoire Français de la Sclérose en Plaques centres. The delay from treatment start to attaining an irreversible Expanded Disability Status Scale (EDSS) score of 3.0 was compared between the early group (N = 1882; treated within 12 months following MS clinical onset) and the later group using propensity score weighted Kaplan–Meier methods, overall and stratified by age. Results: Overall, the restricted mean time before reaching EDSS 3.0 from treatment start was 11 years and 2 months for patients treated within the year following MS clinical onset and 10 years and 7 months for patients treated later. Thus, early treated patients gained 7 months (95% confidence interval [CI] 4–11 months) in the time to reach EDSS 3.0 compared to patients treated later (treatment start delayed by 28 months). The difference in restricted mean time was respectively 6 months (95% CI 1–10 months) and 14 months (95% CI 4–24 months) in the ≤40 years age group and in the >40 years age group, in favour of the early group. Conclusions: Early treatment initiation resulted in a significant reduction of disability progression amongst patients with RRMS, and also amongst older patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

11. The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies

Author

Andersen, Johanna B, primary, Sharmin, Sifat, additional, Lefort, Mathilde, additional, Koch-Henriksen, Nils, additional, Sellebjerg, Finn, additional, Sørensen, Per Soelberg, additional, Hilt Christensen, Claudia C, additional, Rasmussen, Peter V, additional, Jensen, Michael B, additional, Frederiksen, Jette L, additional, Bramow, Stephan, additional, Mathiesen, Henrik K, additional, Schreiber, Karen I, additional, Horakova, Dana, additional, Havrdova, Eva K, additional, Alroughani, Raed, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Ozakbas, Serkan, additional, Patti, Francesco, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Terzi, Murat, additional, Grammond, Pierre, additional, Grand Maison, Francois, additional, Yamout, Bassem, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Boz, Cavit, additional, Trojano, Maria, additional, McCombe, Pamela, additional, Slee, Mark, additional, Lechner-Scott, Jeannette, additional, Turkoglu, Recai, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Granella, Franco, additional, Shaygannejad, Vahid, additional, Prevost, Julie, additional, Skibina, Olga, additional, Solaro, Claudio, additional, Karabudak, Rana, additional, Wijmeersch, Bart V, additional, Csepany, Tunde, additional, Spitaleri, Daniele, additional, Vucic, Steve, additional, Casey, Romain, additional, Debouverie, Marc, additional, Edan, Gilles, additional, Ciron, Jonathan, additional, Ruet, Aurélie, additional, Sèze, Jérôme D, additional, Maillart, Elisabeth, additional, Zephir, Hélène, additional, Labauge, Pierre, additional, Defer, Gilles, additional, Lebrun, Christine, additional, Moreau, Thibault, additional, Berger, Eric, additional, Clavelou, Pierre, additional, Pelletier, Jean, additional, Stankoff, Bruno, additional, Gout, Olivier, additional, Thouvenot, Eric, additional, Heinzlef, Olivier, additional, Al-Khedr, Abdullatif, additional, Bourre, Bertrand, additional, Casez, Olivier, additional, Cabre, Philippe, additional, Montcuquet, Alexis, additional, Wahab, Abir, additional, Camdessanché, Jean-Philippe, additional, Marousset, Aude, additional, Patry, Ivania, additional, Hankiewicz, Karolina, additional, Pottier, Corinne, additional, Maubeuge, Nicolas, additional, Labeyrie, Céline, additional, Nifle, Chantal, additional, Leray, Emmanuelle, additional, Laplaud, David A, additional, Butzkueven, Helmut, additional, Kalincik, Tomas, additional, Vukusic, Sandra, additional, and Magyari, Melinda, additional

Published
2021
Full Text
View/download PDF

12. Impact de la crise sanitaire de la COVID-19 sur la santé mentale des étudiants à Rennes, France

Author

Roux, Jonathan, Lefort, Mathilde, Bertin, Mélanie, Padilla, Cindy, Mueller, Judith, Garlantézec, Ronan, Pivette, Mathilde, Le Tertre, Alain, Crepey, Pascal, Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), École des Hautes Études en Santé Publique [EHESP] (EHESP), Institut Pasteur [Paris] (IP), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Santé publique France - French National Public Health Agency [Saint-Maurice, France], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Institut Pasteur [Paris], Université d'Angers (UA)-Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
Santé mentale, Impact, Crise sanitaire, COVID-19, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, Rennes, Etudiants, [SHS]Humanities and Social Sciences
Abstract

Pour lutter contre la pandémie de Covid-19, la France, comme de nombreux pays dans le monde, a dû mettre en place des mesures de contrôle pour ralentir la propagation du SARS-CoV-2. Ces mesures, qui ont un impact direct sur la vie quotidienne des Français, ne sont pas sans conséquences sur leur santé mentale, notamment pour la population des étudiants. Ainsi, lors du premier confinement en avril 2020 près d'un tiers des étudiants présentait des signes de détresse psychologique d'après une étude nationale. Cependant, aucune donnée n'existe, à notre connaissance, concernant la santé mentale des étudiants suite au second confinement du mois de novembre 2020. Cette étude a pour objectif d'évaluer l'impact de la crise sanitaire de la COVID-19 jusqu'au mois de novembre 2020 en France sur la santé mentale des étudiants au travers de divers indicateurs : détresse psychologique, soutien social, solitude, symptômes de dépression et symptômes d'anxiété. Elle se base sur les données recueillies dans le cadre de l'enquête longitudinale COVER portant plus largement sur les facteurs de risque et les comportements des étudiants de Rennes face à l'épidémie de Covid-19. Dans le cadre de cette enquête, 4261 étudiants Rennais issus de l'EHESP (Ecole des Hautes Etudes en Santé Publique), la Rennes School of Business et Sciences Po Rennes ont été invités en décembre 2020 à répondre à un auto-questionnaire en ligne visant, pour partie, à évaluer leur santé mentale. Parmi les étudiants interrogés, 784 ont répondu au questionnaire (taux de participation de 18.4%). Les résultats ont été redressé pour être représentatifs de la distribution par sexe des étudiants. Les signes d'une détresse psychologique ont été retrouvés chez 60.3% des étudiants interrogés (Intervalle de confiance à 95% (IC95%) [57.0%; 64.1%]). Un étudiant sur cinq présentait des symptômes de dépression (IC95% [20.3%; 26.4%]) et 37.7% des symptômes d'anxiété (IC95% [34.3%; 41.1%]). Plus d'un étudiant sur deux présentait des signes de solitude (IC95% [47.9%; 52.1%]) et près d'un quart bénéficiait d'un faible soutien social (IC95% [19.8%; 25.9%]). Les femmes étaient davantage à risque de détresse psychologique et de symptômes d'anxiété comparativement aux hommes. Par ailleurs, les étudiants qui présentaient des difficultés financières, qui bénéficiaient d'un faible soutien social, qui se déclaraient en mauvaise santé ou qui avaient un sentiment de solitude étaient plus à risque de présenter une détresse psychologique, ainsi que des symptômes d'anxiété ou de dépression. Les prévalences estimées de détresse psychologique, de symptômes dépressifs et anxieux sont inquiétantes dans cette population déjà vulnérable. Les symptômes et signes identifiés sont probablement transitoires, et ne reflètent que l'état psychologique des étudiants le mois précédent la réponse au questionnaire sans poser de diagnostic clinique. Néanmoins, ces résultats invitent à réestimer les risques et les bénéfices des mesures impactant la vie des étudiants. Ils encouragent la mise en place d'actions de prévention des risques psychologiques à destination de ce public, comme des plateformes d'écoutes, le développement du soutien entre pairs ou la mise en place de mesures de contrôle qui permettent une reprise, au moins partielle, des cours en présentiel.

Published
2021

13. The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies

Author

Andersen, Johanna B., Sharmin, Sifat, Lefort, Mathilde, Koch-Henriksen, Nils, Sellebjerg, Finn, Sørensen, Per Soelberg, Hilt Christensen, Claudia C., Rasmussen, Peter V., Jensen, Michael B., Frederiksen, Jette L., Bramow, Stephan, Mathiesen, Henrik K., Schreiber, Karen I., Horakova, Dana, Havrdova, Eva K., Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, McCombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Shaygannejad, Vahid, Prevost, Julie, Skibina, Olga, Solaro, Claudio, Karabudak, Rana, Wijmeersch, Bart V., Csepany, Tunde, Spitaleri, Daniele, Vucic, Steve, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Sèze, Jérôme D., Maillart, Elisabeth, Zephir, Hélène, Labauge, Pierre, Defer, Gilles, Lebrun, Christine, Moreau, Thibault, Berger, Eric, Clavelou, Pierre, Pelletier, Jean, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abdullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanché, Jean Philippe, Marousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Céline, Nifle, Chantal, Leray, Emmanuelle, Laplaud, David A., Butzkueven, Helmut, Kalincik, Tomas, Vukusic, Sandra, Magyari, Melinda, Andersen, Johanna B., Sharmin, Sifat, Lefort, Mathilde, Koch-Henriksen, Nils, Sellebjerg, Finn, Sørensen, Per Soelberg, Hilt Christensen, Claudia C., Rasmussen, Peter V., Jensen, Michael B., Frederiksen, Jette L., Bramow, Stephan, Mathiesen, Henrik K., Schreiber, Karen I., Horakova, Dana, Havrdova, Eva K., Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, McCombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Shaygannejad, Vahid, Prevost, Julie, Skibina, Olga, Solaro, Claudio, Karabudak, Rana, Wijmeersch, Bart V., Csepany, Tunde, Spitaleri, Daniele, Vucic, Steve, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Sèze, Jérôme D., Maillart, Elisabeth, Zephir, Hélène, Labauge, Pierre, Defer, Gilles, Lebrun, Christine, Moreau, Thibault, Berger, Eric, Clavelou, Pierre, Pelletier, Jean, Stankoff, Bruno, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abdullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Wahab, Abir, Camdessanché, Jean Philippe, Marousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Céline, Nifle, Chantal, Leray, Emmanuelle, Laplaud, David A., Butzkueven, Helmut, Kalincik, Tomas, Vukusic, Sandra, and Magyari, Melinda

Abstract

Background: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effective to prevent relapses and EDSS worsening. Methods: By re-analyzing original published results from MSBase, France, and Denmark using uniform methodologies, we aimed at identifying the effects of differences in methodology, in the MS-populations, and at re-evaluating the differences in effectiveness between the two drugs. We gained access to copies of the individual amended databases and pooled all data. We used uniform inclusion/exclusion criteria and statistical methods with Inverse Probability Treatment Weighting. Results: The pooled analyses comprised 968 natalizumab- and 1479 fingolimod treated patients. The on-treatment natalizumab/fingolimod relapse rate ratio was 0.77 (p=0.004). The hazard ratio (HR) for a first relapse was 0.82 (p=0.030), and the HR for sustained EDSS improvement was 1.4 (p=0.009). There were modest differences between each of the original published studies and the replication study, but the conclusions of the three original studies remained unchanged: in two of them natalizumab was more effective, but in the third there was no difference between natalizumab and fingolimod. Conclusion: The results were largely invariant to the epidemiological and statistical methods but differed between the MS populations. Generally, the advantage of natalizumab was confirmed.

Published
2021

14. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis:A Subgroup Analysis From Three International Cohorts

Author

Sharmin, Sifat, Lefort, Mathilde, Andersen, Johanna Balslev, Leray, Emmanuelle, Horakova, Dana, Havrdova, Eva Kubala, Alroughani, Raed, Izquierdo, Guillermo, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand’Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, McCombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Prevost, Julie, Maimone, Davide, Skibina, Olga, Buzzard, Katherine, Van der Walt, Anneke, Van Wijmeersch, Bart, Csepany, Tunde, Spitaleri, Daniele, Vucic, Steve, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Sellebjerg, Finn Thorup, Soerensen, Per Soelberg, Jensen, Michael Broksgaard, Frederiksen, Jette Lautrup, Bramow, Stephan, Mathiesen, Henrik Kahr, Schreiber, Karen Ingrid, Magyari, Melinda, Sharmin, Sifat, Lefort, Mathilde, Andersen, Johanna Balslev, Leray, Emmanuelle, Horakova, Dana, Havrdova, Eva Kubala, Alroughani, Raed, Izquierdo, Guillermo, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand’Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Trojano, Maria, McCombe, Pamela, Slee, Mark, Lechner-Scott, Jeannette, Turkoglu, Recai, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Prevost, Julie, Maimone, Davide, Skibina, Olga, Buzzard, Katherine, Van der Walt, Anneke, Van Wijmeersch, Bart, Csepany, Tunde, Spitaleri, Daniele, Vucic, Steve, Casey, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Sellebjerg, Finn Thorup, Soerensen, Per Soelberg, Jensen, Michael Broksgaard, Frederiksen, Jette Lautrup, Bramow, Stephan, Mathiesen, Henrik Kahr, Schreiber, Karen Ingrid, and Magyari, Melinda

Abstract

Introduction: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined. Objective: The aim of this study was to compare the relative effectiveness of natalizumab and fingolimod in RRMS subgroups defined by the baseline demographic and clinical characteristics of interest. Methods: Patients with RRMS who were given natalizumab or fingolimod were identified in a merged cohort from three international registries. Efficacy outcomes were compared across subgroups based on patients’ sex, age, disease duration, Expanded Disability Status Scale (EDSS) score, and disease and magnetic resonance imaging (MRI) activity 12 months prior to treatment initiation. Study endpoints were number of relapses (analyzed with weighted negative binomial generalized linear model) and 6-month confirmed disability worsening and improvement events (weighted Cox proportional hazards model), recorded during study therapy. Each patient was weighted using inverse probability of treatment weighting based on propensity score. Results: A total of 5148 patients (natalizumab 1989; fingolimod 3159) were included, with a mean ± standard deviation age at baseline of 38 ± 10 years, and the majority (72%) were women. The median on-treatment follow-up was 25 (quartiles 15–41) months. Natalizumab was associated with fewer relapses than fingolimod (incidence rate ratio [IRR]; 95% confidence interval [CI]) in women (0.76; 0.65–0.88); in those aged ≤ 38 years (0.64; 0.54–0.76); in those with disease duration ≤ 7 years (0.63; 0.53–0.76); in those with EDSS score < 4 (0.75; 0.64–0.88), < 6 (0.80; 0.70–0.91), and ≥ 6 (0.52; 0.31–0.86); and in patients with pre-baseline relapses (0.74; 0.64–0.86). A higher probability of confirmed disability improvement on natalizumab versus fingolimod (hazard ratio [HR]; 95% CI) was observed among women (1.36

Published
2021

15. A Cross-sectional Study on Infectious Health Risks Regarding Freshwater Sport Practice in Brittany, France

Author

Velardo, Fanny, primary, Bouziri, Hanifa, additional, Adélaïde, Lucie, additional, Oliosi, Emma, additional, Layan, Maylis, additional, Descamps, Alexandre, additional, Berthod, Delphine, additional, Patlán-Hernández, Alan R., additional, Ledrans, Martine, additional, Pivette, Mathilde, additional, Lefort, Mathilde, additional, Roux, Jonathan, additional, and Crépey, Pascal, additional

Published
2021
Full Text
View/download PDF

16. Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts (2943)

Author

Sharmin, Sifat, primary, Lefort, Mathilde, additional, Andersen, Johanna Balslev, additional, Leray, Emmanuelle, additional, Horakova, Dana, additional, Havrdova, Eva, additional, Alroughani, Raed, additional, Ayuso, Guillermo Izquierdo, additional, Ozakbas, Serkan, additional, Patti, Francesco, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Terzi, Murat, additional, Grammond, Pierre, additional, Grand’Maison, Francois, additional, Yamout, Bassem, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Boz, Cavit, additional, Trojano, Maria, additional, McCombe, Pamela, additional, Slee, Mark, additional, Lechner-Scott, Jeannette, additional, Turkoglu, Recai, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Granella, Franco, additional, Prevost, Julie, additional, Maimone, Davide, additional, Skibina, Olga, additional, Buzzard, Katherine, additional, Van der Walt, Anneke, additional, Van Wijmeersch, Bart, additional, Csepany, Tunde, additional, Spitaleri, Daniele Litterio A., additional, Vucic, Ostoja (Steve), additional, Casey, Romain, additional, Debouverie, Marc, additional, Edan, Gilles, additional, Ciron, Jonathan, additional, Ruet, Aurélie, additional, De Sèze, Jérôme, additional, Maillart, Elisabeth, additional, Zephir, Hélène, additional, Labauge, Pierre, additional, Defer, Gilles, additional, Lebrun-Frénay, Christine, additional, Moreau, Thibault, additional, Berger, Eric, additional, Clavelou, Pierre, additional, Pelletier, Jean, additional, Stankoff, Bruno, additional, Gout, Olivier, additional, Thouvenot, Eric, additional, Heinzlef, Olivier, additional, Al-Khedr, Abullatif, additional, Bourre, Bertrand, additional, Casez, Olivier, additional, Cabre, Philippe, additional, Montcuquet, Alexis, additional, Wahab, Abir, additional, Camdessanché, Jean-Philippe, additional, Maurousset, Aude, additional, Patry, Ivania, additional, Hankiewicz, Karolina, additional, Pottier, Corinne, additional, Maubeuge, Nicolas, additional, Labeyrie, Céline, additional, Nifle, Chantal, additional, Laplaud, David, additional, Koch-Henriksen, Nils, additional, Sellebjerg, Finn Thorup, additional, Soerensen, Per Soelberg, additional, Pfleger, Claudia Christina, additional, Rasmussen, Peter Vestergaard, additional, Jensen, Michael Broksgaard, additional, Frederiksen, Jette Lautrup, additional, Bramow, Stephan, additional, Mathiesen, Henrik Kahr, additional, Schreiber, Karen Ingrid, additional, Magyari, Melinda, additional, Vukusic, Sandra, additional, Butzkueven, Helmut, additional, and Kalincik, Tomas, additional

Published
2021
Full Text
View/download PDF

18. Etude de l'effet des stratégies thérapeutiques en conditions réelles d'utilisation sur la progression du handicap chez les patients atteints de sclérose en plaques rémittente

Author

Lefort, Mathilde, Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes, Emmanuelle Leray, Gilles Edan, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Rennes 1, and STAR, ABES

Subjects
Multiple sclerosis, Efficacité, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Observational data, Propensity score, Données observationnelles, Score de propension, Effectiveness, Disease-Modifying drug, Sclérose en plaques, Traitement de fond, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Multiple sclerosis (MS) is a chronic neurological disease starting in early adulthood. Relapsing-onset MS is the most common phenotype and defined as occurrence of relapses, a relapse being defined as apparition or worsening of new symptoms. At long term, symptoms get worst and lead to irreversible disability. Since the mid-1990s, the arsenal of specific MS disease-modifying drugs has evolved, leading to different therapeutic strategies based on patient’s characteristics and benefit/risk profile of treatment. The main objective of this PhD thesis was to assess the effectiveness of treatments and therapeutic strategies in real-life on disability progression. The secondary objective was to explore the propensity score methods used to control indication bias. This work was based upon observational data from the “Observatoire Français de la Sclérose en plaques” (OFSEP), mainly collected at consultations in MS expert center. This work was organized around three axes. The evaluation of the effect of first-line injectable treatments led to the use of a method based on a time-dependent propensity score. No benefit was shown on long-term outcome, but this result was probably altered by residual confusion. Comparison of second-line treatments (natalizumab and fingolimod) confirmed the superiority of natalizumab on disability progression and provided the opportunity to explore the impact of methods using propensity scores on results. Finally, the different usual therapeutic strategies were described in France, and preliminary results on their effectiveness were proposed., La sclérose en plaques (SEP) est une maladie neurologique chronique affectant le jeune adulte. Dans sa forme la plus fréquente, la forme rémittente, elle évolue par poussée. A long-terme, celles-ci peuvent laisser des séquelles et conduire à un handicap irréversible. Depuis le milieu des années 90, le répertoire des traitements de fond spécifiques de la SEP ne cesse d’évoluer faisant émerger différentes stratégies thérapeutiques, définies à partir des caractéristiques des patients et du profil bénéfice/risque des traitements. L’efficacité des traitements de fond en vie réelle a déjà été explorée mais a conduit à des résultats controversés. L’objectif principal de cette thèse est d’évaluer l’efficacité des traitements et des stratégies thérapeutiques en vie réelle sur la progression du handicap. L’objectif secondaire était d’explorer les méthodes de score de propension, utilisées dans le but de contrôler le biais d’indication. Ce travail a été réalisé à partir des données de l’Observatoire Français de la Sclérose en Plaques (OFSEP), principalement collectées au cours des consultations en centre expert SEP. Ce travail a été organisé autour de trois axes. L’évaluation de l’effet des traitements de première ligne injectables a mené à utiliser une méthode basée sur un score de propension dépendant du temps, conduisant à ne pas montrer de bénéfice à long terme, résultat probablement altéré par de la confusion résiduelle. La comparaison de deux traitements de deuxième ligne, natalizumab et fingolimod, a conduit à confirmer la supériorité du natalizumab sur la progression du handicap et a offert l‘opportunité d’explorer l’impact des méthodes utilisant les scores de propension sur les résultats. Enfin, les différentes stratégies thérapeutiques ont été décrites en France, des résultats préliminaires sur leur efficacité ont été proposés.

Published
2019

20. Long-term effect of interferon and Glatiramer acetate in real-world settings use on multiple sclerosis disability progression: Input of time-dependent propensity score

Author

Lefort, Mathilde, Foucher, Yohann, Lenain, Rémi, Vukusic, Sandra, Edan, Gilles, Leray, Emmanuelle, Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), École des Hautes Études en Santé Publique [EHESP] (EHESP), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Nantes (CHU Nantes), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Service de Neurologie [CHU Rennes], CHU Pontchaillou [Rennes], Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Jonchère, Laurent

Subjects
[SDV] Life Sciences [q-bio], Glatiramer acetate, [SDV]Life Sciences [q-bio], Interferon, Multiple sclerosis (MS), ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

21. Studying effects of real-life therapeutic strategies on disability progression in patients with relapsing-onset multiple sclerosis

Author

Lefort, Mathilde, STAR, ABES, Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Rennes 1, Emmanuelle Leray, and Gilles Edan

Subjects
Multiple sclerosis, Efficacité, Observational data, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Propensity score, Données observationnelles, Score de propension, Effectiveness, Disease-Modifying drug, Sclérose en plaques, Traitement de fond, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Multiple sclerosis (MS) is a chronic neurological disease starting in early adulthood. Relapsing-onset MS is the most common phenotype and defined as occurrence of relapses, a relapse being defined as apparition or worsening of new symptoms. At long term, symptoms get worst and lead to irreversible disability. Since the mid-1990s, the arsenal of specific MS disease-modifying drugs has evolved, leading to different therapeutic strategies based on patient’s characteristics and benefit/risk profile of treatment. The main objective of this PhD thesis was to assess the effectiveness of treatments and therapeutic strategies in real-life on disability progression. The secondary objective was to explore the propensity score methods used to control indication bias. This work was based upon observational data from the “Observatoire Français de la Sclérose en plaques” (OFSEP), mainly collected at consultations in MS expert center. This work was organized around three axes. The evaluation of the effect of first-line injectable treatments led to the use of a method based on a time-dependent propensity score. No benefit was shown on long-term outcome, but this result was probably altered by residual confusion. Comparison of second-line treatments (natalizumab and fingolimod) confirmed the superiority of natalizumab on disability progression and provided the opportunity to explore the impact of methods using propensity scores on results. Finally, the different usual therapeutic strategies were described in France, and preliminary results on their effectiveness were proposed., La sclérose en plaques (SEP) est une maladie neurologique chronique affectant le jeune adulte. Dans sa forme la plus fréquente, la forme rémittente, elle évolue par poussée. A long-terme, celles-ci peuvent laisser des séquelles et conduire à un handicap irréversible. Depuis le milieu des années 90, le répertoire des traitements de fond spécifiques de la SEP ne cesse d’évoluer faisant émerger différentes stratégies thérapeutiques, définies à partir des caractéristiques des patients et du profil bénéfice/risque des traitements. L’efficacité des traitements de fond en vie réelle a déjà été explorée mais a conduit à des résultats controversés. L’objectif principal de cette thèse est d’évaluer l’efficacité des traitements et des stratégies thérapeutiques en vie réelle sur la progression du handicap. L’objectif secondaire était d’explorer les méthodes de score de propension, utilisées dans le but de contrôler le biais d’indication. Ce travail a été réalisé à partir des données de l’Observatoire Français de la Sclérose en Plaques (OFSEP), principalement collectées au cours des consultations en centre expert SEP. Ce travail a été organisé autour de trois axes. L’évaluation de l’effet des traitements de première ligne injectables a mené à utiliser une méthode basée sur un score de propension dépendant du temps, conduisant à ne pas montrer de bénéfice à long terme, résultat probablement altéré par de la confusion résiduelle. La comparaison de deux traitements de deuxième ligne, natalizumab et fingolimod, a conduit à confirmer la supériorité du natalizumab sur la progression du handicap et a offert l‘opportunité d’explorer l’impact des méthodes utilisant les scores de propension sur les résultats. Enfin, les différentes stratégies thérapeutiques ont été décrites en France, des résultats préliminaires sur leur efficacité ont été proposés.

Published
2019

22. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.

Author

Sharmin, Sifat, Lefort, Mathilde, Andersen, Johanna Balslev, Leray, Emmanuelle, Horakova, Dana, Havrdova, Eva Kubala, Alroughani, Raed, Izquierdo, Guillermo, Ozakbas, Serkan, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Terzi, Murat, Grammond, Pierre, Grand'Maison, Francois, Yamout, Bassem, Prat, Alexandre, Girard, Marc, Duquette, Pierre, and Boz, Cavit

Subjects
*NATALIZUMAB, *PROPORTIONAL hazards models, *MAGNETIC resonance imaging, *DISEASE relapse, *MULTIPLE sclerosis, *FINGOLIMOD, *SUBGROUP analysis (Experimental design)
Abstract

Introduction: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined. Objective: The aim of this study was to compare the relative effectiveness of natalizumab and fingolimod in RRMS subgroups defined by the baseline demographic and clinical characteristics of interest. Methods: Patients with RRMS who were given natalizumab or fingolimod were identified in a merged cohort from three international registries. Efficacy outcomes were compared across subgroups based on patients' sex, age, disease duration, Expanded Disability Status Scale (EDSS) score, and disease and magnetic resonance imaging (MRI) activity 12 months prior to treatment initiation. Study endpoints were number of relapses (analyzed with weighted negative binomial generalized linear model) and 6-month confirmed disability worsening and improvement events (weighted Cox proportional hazards model), recorded during study therapy. Each patient was weighted using inverse probability of treatment weighting based on propensity score. Results: A total of 5148 patients (natalizumab 1989; fingolimod 3159) were included, with a mean ± standard deviation age at baseline of 38 ± 10 years, and the majority (72%) were women. The median on-treatment follow-up was 25 (quartiles 15–41) months. Natalizumab was associated with fewer relapses than fingolimod (incidence rate ratio [IRR]; 95% confidence interval [CI]) in women (0.76; 0.65–0.88); in those aged ≤ 38 years (0.64; 0.54–0.76); in those with disease duration ≤ 7 years (0.63; 0.53–0.76); in those with EDSS score < 4 (0.75; 0.64–0.88), < 6 (0.80; 0.70–0.91), and ≥ 6 (0.52; 0.31–0.86); and in patients with pre-baseline relapses (0.74; 0.64–0.86). A higher probability of confirmed disability improvement on natalizumab versus fingolimod (hazard ratio [HR]; 95% CI) was observed among women (1.36; 1.10–1.66); those aged > 38 years (1.34; 1.04–1.73); those with disease duration > 7 years (1.33; 1.01–1.74); those with EDSS score < 6 (1.21; 1.01–1.46) and ≥ 6 (1.93; 1.11–3.34); and patients with no new MRI lesion (1.73; 1.19–2.51). Conclusions: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

23. Two-year management after renal transplantation in 2013 in France: Input from the French national health system database

Author

Le Meur, Nolwenn, Lefort, Mathilde, Lebbah, Saïd, Jais, Jean-Philippe, Daugas, Eric, Bayat, Sahar, Tuppin, Philippe, Bessou, Antoine, Legeai, Camille, Vigneau, Cécile, Couchoud, Cécile, École des Hautes Études en Santé Publique [EHESP] (EHESP), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'informatique médicale et biostatistiques [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), UMR 1599, Centre National de la Recherche Scientifique (CNRS), Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Agence de la biomédecine [Saint-Denis la Plaine], Hôpital Ambroise Paré [AP-HP], CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Université d'Angers (UA)-Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
Adult, Male, Pediatrics, medicine.medical_specialty, Healthcare use, Databases, Factual, 030232 urology & nephrology, Disease, 030230 surgery, Mycophenolic acid, Kidney transplantation, 03 medical and health sciences, 0302 clinical medicine, Observational study, Health care, medicine, Humans, National health, business.industry, Follow-up, Length of Stay, Middle Aged, Patient Acceptance of Health Care, Ciclosporin, medicine.disease, Tacrolimus, 3. Good health, Transplantation, Hospitalization, Treatment, Nephrology, Kidney Failure, Chronic, Female, France, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, medicine.drug, Follow-Up Studies
Abstract

International audience; The objective of this study was to describe the management of patients undergoing renal transplantation in 2013 and over the following two years on the basis of healthcare consumption data. The National Health Insurance Information System was used to identify 1876 general scheme beneficiaries undergoing a first isolated renal transplantation (median age: 53 years; men 63%). Overall, 1.2% of patients died during the transplantation hospital stay (>65 years 3.3%) and 87% of patients had a functional graft at 2 years. Thirty-three percent of patients were readmitted to hospital for 1 day or longer during the first month, 73% the first year and 55% the second year. At least 10% of patients were hospitalised for antirejection treatment during the first quarter after renal transplantation, 16% the first year and 9% the second year. The first year, 32% of patients were hospitalised for renal disease (12% the second year), 14% were hospitalised for cardiovascular disease (9% the second year), 13% for infectious disease (5% the second year) and 2% for a malignant tumour (2% the second year). Almost 80% of patients consulted their general practitioner each year (almost 50% consulted every quarter). During the second year, 83% of patients were taking antihypertensives, 45% lipid-lowering drugs, 26% antidiabetic drugs, 77% tacrolimus, 18% ciclosporin, 88% mycophenolic acid and 69% corticosteroids. This study highlights the important contribution of healthcare consumption data to a better understanding of the modalities of management of renal transplant recipients in France, allowing improvement of this management in line with guidelines.

Published
2018

24. Supplemental material for Categorical state sequence analysis and regression tree to identify determinants of care trajectory in chronic disease: Example of end-stage renal disease

Author

Meur, Nolwenn Le, Vigneau, Cécile, Lefort, Mathilde, Saïd Lebbah, Jean-Philippe Jais, Daugas, Eric, and Bayat, Sahar

Subjects
111099 Nursing not elsewhere classified, 111708 Health and Community Services, 160807 Sociological Methodology and Research Methods, FOS: Health sciences, FOS: Sociology
Abstract

Supplemental material for Categorical state sequence analysis and regression tree to identify determinants of care trajectory in chronic disease: Example of end-stage renal disease by Nolwenn Le Meur, Cécile Vigneau, Mathilde Lefort, Saïd Lebbah, Jean-Philippe Jais, Eric Daugas and Sahar Bayat in Statistical Methods in Medical Research

Published
2018
Full Text
View/download PDF

25. Propensity score methods The study of the effect of beta-interferon and glatiramer acetate on multiple sclerosis disability

Author

Lefort, Mathilde, Edan, Gilles, Leray, Emmanuelle, Jonchère, Laurent, École des Hautes Études en Santé Publique [EHESP] (EHESP), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

28. Hilar Fat Infiltration: An Independent Prognostic Factor in Metastatic Clear Cell Renal Cell Carcinoma with Sunitinib First-Line Treatment

Author

Kammerer-Jacquet, Solène-Florence, Brunot, Angélique, Benasalah, Karim, Campillo-Gimenez, Boris, Lefort, Mathilde, Bayat, Sahar, Ravaud, Alain, Dupuis, Frantz, Yacoub, Mokrane, Verhoest, Grégory, Mathieu, Romain, Peyronnet, Benoit, Lespagnol, Alexandra, Mosser, Jean, Edeline, Julien, Laguerre, Brigitte, Bernhard, Jean-Christophe, Rioux-Leclercq, Nathalie, Service de Pathologie [Rennes] = Pathology [Rennes], CHU Pontchaillou [Rennes], Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CRLCC Eugène Marquis (CRLCC), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département Méthodes quantitatives en santé publique (METIS), École des Hautes Études en Santé Publique [EHESP] (EHESP), Service d'Oncologie Médicale [Bordeaux], Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, French Network for Research on Kidney Cancer (UroCCR), Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Institut des Sciences Cognitives (ISC), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Foie, métabolismes et cancer, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Département d'oncologie médicale [Rennes], Service d'urologie, andrologie et transplantation rénale, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Jonchère, Laurent, Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
Clear cell renal cell carcinoma, Hilar fat infiltration, [SDV.GEN]Life Sciences [q-bio]/Genetics, Sunitinib, [SDV.GEN] Life Sciences [q-bio]/Genetics, Prognostic, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

29. Nomogram Predicting Prognosis in Metastatic Patients with Clear Cell Renal Cell Carcinoma Treated by First-Line Sunitinib

Author

Kammerer-Jacquet, Solène-Florence, Dugay, Frédéric, Bensalah, Karim, Brunot, Angélique, Peyronnet, Benoit, Mathieu, Romain, Verhoest, Grégory, Lefort, Mathilde, Bayat, Sahar, Lespagnol, Alexandra, Mosser, Jean, Edeline, Julien, Laguerre, Brigitte, Dupuis, Frantz, Yacoub, Mokrane, Ravaud, Alain, Bernhard, Jean-Christophe, Belaud-Rotureau, Marc-Antoine, Rioux-Leclercq, Nathalie, Service de Pathologie [Rennes] = Pathology [Rennes], CHU Pontchaillou [Rennes], Institut de Génétique et Développement de Rennes (IGDR), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Service de Cytogénétique et de Biologie Cellulaire, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], CRLCC Eugène Marquis (CRLCC), Département Méthodes quantitatives en santé publique (METIS), École des Hautes Études en Santé Publique [EHESP] (EHESP), Foie, métabolismes et cancer, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Département d'oncologie médicale [Rennes], Service d'Oncologie Médicale [Bordeaux], Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, French Network for Research on Kidney Cancer (UroCCR), Service d'urologie, andrologie et transplantation rénale, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Jonchère, Laurent, Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
[SDV.GEN]Life Sciences [q-bio]/Genetics, [SDV.GEN] Life Sciences [q-bio]/Genetics
Abstract

International audience; 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), San Antonio, TX, 2017-03-04

Published
2017

33. Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment

Author

Kammerer-Jacquet, Solène-Florence, primary, Brunot, Angelique, additional, Bensalah, Karim, additional, Campillo-Gimenez, Boris, additional, Lefort, Mathilde, additional, Bayat, Sahar, additional, Ravaud, Alain, additional, Dupuis, Frantz, additional, Yacoub, Mokrane, additional, Verhoest, Gregory, additional, Peyronnet, Benoit, additional, Mathieu, Romain, additional, Lespagnol, Alexandra, additional, Mosser, Jean, additional, Edeline, Julien, additional, Laguerre, Brigitte, additional, Bernhard, Jean-Christophe, additional, and Rioux-Leclercq, Nathalie, additional

Published
2017
Full Text
View/download PDF

36. Categorical state sequence analysis and regression tree to identify determinants of care trajectory in chronic disease: Example of end-stage renal disease.

Author

Le Meur, Nolwenn, Vigneau, Cécile, Lefort, Mathilde, Lebbah, Saïd, Jais, Jean-Philippe, Daugas, Eric, and Bayat, Sahar

Subjects
CHRONIC kidney failure, REGRESSION analysis, REGRESSION trees, SEQUENCE analysis, CHRONIC diseases, DIALYSIS catheters
Abstract

Background: Patients with chronic diseases, like patients with end-stage renal disease (ESRD), have long history of care driven by multiple determinants (medical, social, economic, etc.). Although in most epidemiological studies, analyses of health care determinants are computed on single health care events using classical multivariate statistical regression methods. Only few studies have integrated the concept of treatment trajectories as a whole and studied their determinants.Methods: All 18- to 80-year-old incident ESRD patients who started dialysis in Ile-de-France or Bretagne between 2006 and 2009 and could be followed for a period of 48 months after initiation of a renal replacement therapy were included (n = 5568). Their care trajectories were defined as categorical state sequences. Associations between patients' characteristics and care trajectories were assessed using a regression tree model together with a discrepancy analysis.Results: On average, each patient experienced 1.56 different renal replacement therapies (min = 1; max = 5) during the 48 months of follow-up. About 55% of patients never changed treatment and only 1% tried three or more renal replacement therapy modalities. Twelve homogeneous care trajectory groups were identified. Covariates explained 12% of the discrepancy between groups, particularly age, regions and initiation of hemodialysis with a catheter.Conclusions: Regression tree analysis of categorical state sequence highlighted geographical disparities in the care trajectory of French patients with ESRD that cannot be observed when focusing on a single outcome, such as survival. This method is an original tool to visualize and characterize care trajectories, notably in the context of chronic condition like ESRD. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

38. Estimating sharka dispersal function by stochastic spatiotemporal modelling

Author

Lefort, Mathilde, Dallot, Sylvie, Thébaud, Gael, Labonne, Gerard, Jacquot, Emmanuel, BONNOT, FRANCOIS, Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad), Biologie et Génétique des interactions Plantes-parasites pour la Protection Intégrée, Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut National de la Recherche Agronomique (INRA)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), and ProdInra, Migration

Subjects
[SDV.SA]Life Sciences [q-bio]/Agricultural sciences, [SDV.SA] Life Sciences [q-bio]/Agricultural sciences, U10 - Méthodes mathématiques et statistiques, [SDV.BV]Life Sciences [q-bio]/Vegetal Biology, [SDV.BV] Life Sciences [q-bio]/Vegetal Biology, H10 - Ravageurs des plantes
Abstract

National audience; Plant viral diseases, and especially the ones transmitted by aerial vectors, can cause considerable yield losses. A good knowledge of the distances of spread is key to the understanding of disease dynamics. Exploratory approaches aiming at characterizing the spatiotemporal distribution of diseased plants are often used to get an insight into the distances of spread. A more powerful approach is based on stochastic spatiotemporal modelling in order to estimate the dispersal function of the disease (probability density function describing the probability for an infectious plant to infect a healthy plant at distance d). In this study, we implemented a method for estimating the dispersal function of the sharka disease. Sharka is one of the most serious diseases of stone fruit trees (Prunus sp.). It is caused by Plum pox virus (PPV, genus Potyvirus), transmitted by at least twenty different aphid species in a non persistent manner. Due to the inefficiency of insecticides and the very rare sources of resistance against the virus available in the host species, prophylactic disease control is based on the removal of the diseased trees in the orchards. Thus, a very good knowledge of the dispersal function of sharka is crucial for building epidemiological models and optimizing the strategies of surveillance and control. We adapted the methodology published by Gibson (1997) based on a Markov chain Monte Carlo (MCMC) algorithm in order to estimate sharka dispersal function from the maps of 157 contiguous peach orchards reporting the exact location and the sanitary status (asymptomatic/symptomatic) of each of the trees during six consecutive years. An estimation method based on the Gibbs sampling algorithm was developed taking into account the specificities of the dataset (more than two dates of observation, annual removal of diseased trees). This estimation algorithm was validated on simulated data and was proved to be more powerful and better adapted to large datasets than the one proposed by Gibson. Moreover, the influence of latency on the estimation of the dispersal function was quantified. This methodology was then used to estimate the dispersal function of the disease from a subset of the real dataset. The methods developed in this study are generic enough to be used and adapted for the estimation of dispersal functions of any disease transmitted in a non persistent manner, and even for diseases with similar characteristics. (Texte intégral)

Published
2013

39. [Glioblastoma and nursing care in neurosurgery].

Author

Lefort M

Subjects
Brain Neoplasms surgery, Glioblastoma surgery, Humans, Neurosurgery nursing, Neurosurgery organization & administration, Oncology Nursing methods, Oncology Nursing organization & administration, Practice Patterns, Nurses', Brain Neoplasms nursing, Glioblastoma nursing, Neurosurgical Procedures nursing
Abstract

Nurses in neurosurgical departments play a critical role as they are involved in the first stages of the care pathway of patients with glioblastoma. Indeed, surgery enables a definitive histopathological diagnosis to be established and the size of the tumour to be significantly reduced, thereby improving the prognosis., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results